Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
AMGEN Inc and UCB SA no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.
The drug, romosozumab, which would be sold under the brand name...